サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1664474

男性性腺機能低下症の世界市場レポート 2025年

Male Hypogonadism Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
男性性腺機能低下症の世界市場レポート 2025年
出版日: 2025年02月27日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

男性性腺機能低下症の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.2％で50億8,000万米ドルに成長します。予測期間の成長は、認知度の向上、ライフスタイルに関連した疾患の流行、治療法の革新、男性の健康の重視、遠隔医療、ヘルスケアへのアクセスのしやすさなどに起因しています。予測期間における主な動向としては、心理的・性的健康への注目、栄養補助食品や生活習慣への介入の探求、新興国における市場拡大、共同研究の取り組み、長期的な安全性とモニタリングの重視などが挙げられます。

不妊率の上昇は、今後数年間の男性性腺機能低下症市場の成長を牽引すると予測されます。不妊症とは、男性または女性の生殖器系に影響を及ぼす症状であり、避妊をせずに12ヶ月以上定期的に性交渉を行っても妊娠できない状態と定義されます。男性不妊症の潜在的な原因のひとつに、精子生産量の減少や不妊症の原因となる男性性腺機能低下症があります。その結果、男性不妊症の有病率の増加が男性性腺機能低下症市場を押し上げると予想されます。例えば、2024年2月、英国の政府機関である国家統計局は、2022年の合計特殊出生率（TFR）が2021年の1.55人から1.49人に低下したと報告しました。このように、不妊率の上昇は男性性腺機能低下症市場の成長に大きく寄与しています。

慢性疾患の有病率の上昇は、今後の男性性腺機能低下症市場の成長を大きく牽引すると予測されています。慢性疾患とは、1年以上継続し、継続的な医療を必要とし、多くの場合、日常生活またはその両方を制限する疾患と定義されます。肥満、糖尿病、メタボリックシンドロームなどの病態は、ホルモン産生経路を頻繁にブロックし、テストステロンの合成と調節に影響を及ぼすため、男性性腺機能低下症の発生率が高くなります。例えば、2022年1月、米国を拠点とするがん啓発の非営利団体である米国がん協会（American Cancer Society）は、米国では新たに約190万人のがん患者が発生し、60万9,360人ががんに関連して死亡すると推定しており、これは毎日約1,670人が死亡していることに相当します。世界的に見て、最も罹患率の高いがんは肺がん、前立腺がん、大腸がん、乳がんで、新たに診断された症例の43％を占めています。したがって、慢性疾患の有病率の増加が男性性腺機能低下症市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の男性性腺機能低下症市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の男性性腺機能低下症市場：成長率分析
  • 世界の男性性腺機能低下症市場の実績：規模と成長、2019～2024年
  • 世界の男性性腺機能低下症市場の予測：規模と成長、2024～2029年、2034年
  • 世界の男性性腺機能低下症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の男性性腺機能低下症市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • クラインフェルター症候群
  • カルマン症候群
  • 下垂体疾患
  • その他
  • 世界の男性性腺機能低下症市場：薬剤送達別、実績と予測、2019～2024年、2024～2029年、2034年
  • 局所ジェル
  • 注射剤
  • 経皮パッチ
  • その他
  • 世界の男性性腺機能低下症市場：治療法別、実績と予測、2019～2024年、2024～2029年、2034年
  • テストステロン療法
  • ゴナドトロピン放出ホルモン療法
  • 世界の男性性腺機能低下症市場：クラインフェルター症候群のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 47,XXY症候群
  • その他
  • 世界の男性性腺機能低下症市場：カルマン症候群のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 孤立性カルマン症候群
  • 症候群性カルマン症候群
  • 世界の男性性腺機能低下症市場：下垂体疾患のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 下垂体機能低下症
  • 下垂体腫瘍
  • その他
  • 世界の男性性腺機能低下症市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • アンドロゲン不応症
  • 精巣形成不全症候群
  • 遺伝子変異と疾患

第7章 地域別・国別分析

  • 世界の男性性腺機能低下症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の男性性腺機能低下症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 男性性腺機能低下症市場：競合情勢
  • 男性性腺機能低下症市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Eli Lilly and Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Endo International plc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Ferring Pharmaceuticals
  • Finox Biotech AG
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Perrigo Company plc
  • IBSA Institut Biochimique SA
  • Sun Pharmaceutical Industries Limited
  • Glenmark Pharmaceuticals Limited
  • Antares Pharma Inc.
  • Zydus Cadila LLC
  • Besins Healthcare Ltd.
  • Clarus Therapeutics Holdings Inc.
  • Foresee Pharmaceuticals Co. Ltd.
  • Lipocine Inc.
  • Myovant Sciences Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 男性性腺機能低下症市場2029年：新たな機会を提供する国
  • 男性性腺機能低下症市場2029年：新たな機会を提供するセグメント
  • 男性性腺機能低下症市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r23533

Male hypogonadism is a condition characterized by insufficient production of the hormone testosterone in the body. Testosterone plays a crucial role as the primary male sex hormone, and its presence is vital for the development and growth of men during puberty.

The main types of male hypogonadism include Klinefelter syndrome, Kallmann syndrome, pituitary disorders, and others. Klinefelter syndrome is a hereditary disorder that manifests in boys when they have an extra copy of the X chromosome at birth. Treatment for male hypogonadism often involves testosterone therapy delivered through various methods such as topical gels, injectables, transdermal patches, and gonadotropin-releasing hormone therapy.

The male hypogonadism market research report is one of a series of new reports from The Business Research Company that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends, and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The male hypogonadism market size has grown strongly in recent years. It will grow from $3.75 billion in 2024 to $3.99 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to aging population, awareness and diagnosis, lifestyle factors, chronic illnesses, treatment seeking behavior.

The male hypogonadism market size is expected to see strong growth in the next few years. It will grow to $5.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness, prevalence of lifestyle-related conditions, innovations in therapies, emphasis on men's health, telemedicine and healthcare accessibility. Major trends in the forecast period include attention to psychological and sexual health, exploration of nutraceuticals and lifestyle interventions, market expansion in emerging economies, collaborative research initiatives, focus on long-term safety and monitoring.

The rising infertility rates are projected to drive growth in the male hypogonadism market in the coming years. Infertility is a condition that affects the male or female reproductive system, defined as the inability to conceive after 12 months or more of regular, unprotected sexual intercourse. Male hypogonadism, which can result in reduced sperm production and infertility, is one potential cause of male infertility. Consequently, the increasing prevalence of male infertility is expected to boost the male hypogonadism market. For instance, in February 2024, the Office for National Statistics, a UK-based government department, reported that the total fertility rate (TFR) in 2022 fell to 1.49 children per woman, down from 1.55 in 2021. Thus, the rising infertility rate is significantly contributing to the growth of the male hypogonadism market.

The rising prevalence of chronic diseases is anticipated to significantly drive the growth of the male hypogonadism market in the future. Chronic diseases are defined as conditions that last for a year or longer and require ongoing medical care, often limiting daily activities or both. Conditions such as obesity, diabetes, and metabolic syndrome frequently disrupt hormone production pathways, leading to a higher incidence of male hypogonadism due to their effects on testosterone synthesis and regulation. For example, in January 2022, the American Cancer Society, a U.S.-based cancer awareness nonprofit organization, estimated that there would be approximately 1.9 million new cancer cases and 609,360 cancer-related deaths in the U.S., equating to about 1,670 deaths daily. Globally, the most prevalent cancers include lung, prostate, colorectal, and breast cancers, which account for 43 percent of all newly diagnosed cases. Therefore, the increasing prevalence of chronic diseases is driving the growth of the male hypogonadism market.

A prominent trend is the increasing popularity of product innovations. Companies within this sector are actively pursuing the development of novel products to maintain their competitive positions. For example, in June 2022, Halozyme, a biotechnology company based in the United States, introduced Tlando, an oral treatment designed for testosterone replacement therapy in male hypogonadism. Tlando, a prescription drug containing testosterone, represents a milestone as the first FDA-approved oral testosterone treatment. Its application is targeted at adult men experiencing low or no testosterone due to specific medical conditions.

Major players in the male hypogonadism market are strategically directing their efforts toward creating innovative products, including digital-forward platforms. These platforms aim to engage patients through telemedicine, provide educational resources, and simplify access to treatments, thereby revolutionizing the care landscape for male hypogonadism while enhancing patient support and treatment accessibility. An illustrative example is Base Healthcare, a U.S.-based men's virtual health platform, which, in October 2022, launched a subscription-based platform exclusively for men. This digital health platform prioritizes fundamental health and hormone enhancement through oral testosterone treatment, offering users convenient access to adequate testosterone therapy (ATT), certified medical professionals, and personalized health guidance.

In July 2022, Gruenenthal, a pharmaceutical company headquartered in Germany, acquired Nebido from Bayer AG for €500 million ($551.32 million). This acquisition is strategically aimed at enhancing Gruenenthal's profitability and enabling increased investment in research and development to pave the way for the next generation of pain therapies. Bayer AG, a renowned German pharmaceutical company, plays a pivotal role in the male hypogonadism treatment sector, further influencing the market landscape.

Major companies operating in the male hypogonadism market include Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, IBSA Institut Biochimique SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Myovant Sciences Ltd., Sandoz International GmbH, Shionogi & Co. Ltd., TherapeuticsMD Inc., Viking Therapeutics Inc.

North America was the largest region in the male hypogonadism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The male hypogonadism market includes revenues earned by entities through hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Male Hypogonadism Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on male hypogonadism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for male hypogonadism ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The male hypogonadism market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Klinefelters Syndrome; Kallmann Syndrome; Pituitary Disorders; Other Types
  • 2) By Drug Delivery: Topical Gels; Injectables; Transdermal Patches; Other Drug Deliveries
  • 3) By Therapy: Testosterone Therapy; Gonadotropin-Releasing Hormone Therapy
  • Subsegments:
  • 1) By Klinefelter's Syndrome: 47,XXY Syndrome; Other Variants
  • 2) By Kallmann Syndrome: Isolated Kallmann Syndrome; Syndromic Kallmann Syndrome
  • 3) By Pituitary Disorders: Hypopituitarism; Pituitary Tumors; Other Pituitary Disorders
  • 4) By Other Types: Androgen Insensitivity Syndrome; Testicular Dysgenesis Syndrome; Genetic Mutations And Disorders
  • Companies Mentioned: Pfizer Inc.; Bayer AG; Eli Lilly and Company Ltd.; Endo International plc.; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Male Hypogonadism Market Characteristics

3. Male Hypogonadism Market Trends And Strategies

4. Male Hypogonadism Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Male Hypogonadism Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Male Hypogonadism PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Male Hypogonadism Market Growth Rate Analysis
  • 5.4. Global Male Hypogonadism Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Male Hypogonadism Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Male Hypogonadism Total Addressable Market (TAM)

6. Male Hypogonadism Market Segmentation

  • 6.1. Global Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Klinefelters Syndrome
  • Kallmann Syndrome
  • Pituitary Disorders
  • Other Types
  • 6.2. Global Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Gels
  • Injectables
  • Transdermal Patches
  • Other Drug Deliveries
  • 6.3. Global Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Testosterone Therapy
  • Gonadotropin-Releasing Hormone Therapy
  • 6.4. Global Male Hypogonadism Market, Sub-Segmentation Of Klinefelter's Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 47,XXY Syndrome
  • Other Variants
  • 6.5. Global Male Hypogonadism Market, Sub-Segmentation Of Kallmann Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Isolated Kallmann Syndrome
  • Syndromic Kallmann Syndrome
  • 6.6. Global Male Hypogonadism Market, Sub-Segmentation Of Pituitary Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hypopituitarism
  • Pituitary Tumors
  • Other Pituitary Disorders
  • 6.7. Global Male Hypogonadism Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Androgen Insensitivity Syndrome
  • Testicular Dysgenesis Syndrome
  • Genetic Mutations And Disorders

7. Male Hypogonadism Market Regional And Country Analysis

  • 7.1. Global Male Hypogonadism Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Male Hypogonadism Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Male Hypogonadism Market

  • 8.1. Asia-Pacific Male Hypogonadism Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Male Hypogonadism Market

  • 9.1. China Male Hypogonadism Market Overview
  • 9.2. China Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Male Hypogonadism Market

  • 10.1. India Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Male Hypogonadism Market

  • 11.1. Japan Male Hypogonadism Market Overview
  • 11.2. Japan Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Male Hypogonadism Market

  • 12.1. Australia Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Male Hypogonadism Market

  • 13.1. Indonesia Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Male Hypogonadism Market

  • 14.1. South Korea Male Hypogonadism Market Overview
  • 14.2. South Korea Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Male Hypogonadism Market

  • 15.1. Western Europe Male Hypogonadism Market Overview
  • 15.2. Western Europe Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Male Hypogonadism Market

  • 16.1. UK Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Male Hypogonadism Market

  • 17.1. Germany Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Male Hypogonadism Market

  • 18.1. France Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Male Hypogonadism Market

  • 19.1. Italy Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Male Hypogonadism Market

  • 20.1. Spain Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Male Hypogonadism Market

  • 21.1. Eastern Europe Male Hypogonadism Market Overview
  • 21.2. Eastern Europe Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Male Hypogonadism Market

  • 22.1. Russia Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Male Hypogonadism Market

  • 23.1. North America Male Hypogonadism Market Overview
  • 23.2. North America Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Male Hypogonadism Market

  • 24.1. USA Male Hypogonadism Market Overview
  • 24.2. USA Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Male Hypogonadism Market

  • 25.1. Canada Male Hypogonadism Market Overview
  • 25.2. Canada Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Male Hypogonadism Market

  • 26.1. South America Male Hypogonadism Market Overview
  • 26.2. South America Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Male Hypogonadism Market

  • 27.1. Brazil Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Male Hypogonadism Market

  • 28.1. Middle East Male Hypogonadism Market Overview
  • 28.2. Middle East Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Male Hypogonadism Market

  • 29.1. Africa Male Hypogonadism Market Overview
  • 29.2. Africa Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Male Hypogonadism Market Competitive Landscape And Company Profiles

  • 30.1. Male Hypogonadism Market Competitive Landscape
  • 30.2. Male Hypogonadism Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Eli Lilly and Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Endo International plc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Male Hypogonadism Market Other Major And Innovative Companies

  • 31.1. Ferring Pharmaceuticals
  • 31.2. Finox Biotech AG
  • 31.3. Teva Pharmaceutical Industries Ltd.
  • 31.4. AbbVie Inc.
  • 31.5. Perrigo Company plc
  • 31.6. IBSA Institut Biochimique SA
  • 31.7. Sun Pharmaceutical Industries Limited
  • 31.8. Glenmark Pharmaceuticals Limited
  • 31.9. Antares Pharma Inc.
  • 31.10. Zydus Cadila LLC
  • 31.11. Besins Healthcare Ltd.
  • 31.12. Clarus Therapeutics Holdings Inc.
  • 31.13. Foresee Pharmaceuticals Co. Ltd.
  • 31.14. Lipocine Inc.
  • 31.15. Myovant Sciences Ltd.

32. Global Male Hypogonadism Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Male Hypogonadism Market

34. Recent Developments In The Male Hypogonadism Market

35. Male Hypogonadism Market High Potential Countries, Segments and Strategies

  • 35.1 Male Hypogonadism Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Male Hypogonadism Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Male Hypogonadism Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer